Yumin L., Hao C., Xun L., et al. A new immunomodulatory therapy for severe sepsis: ulinastatin plus thymosin a 1. J Intensive Care Med. 2009 ;24:47-53.
2.
Andreone P., Gramenzi A., Cursaro C., et al. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. J Viral Hepat. 2004;11:69-73.
3.
Bozza S., Gaziano R., Bonifazi P., et al. Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. Int Immunol. 2007;19:1261-1270.
4.
Armutcu F., Coskun O., Gürel A., et al. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin Biochem. 2005;38: 540-547.
5.
Ma LN, Chen XY, Chen J., Huang YL, Shen CLA clinical study of thymosin alpha1 as an auxiliary in treating spontaneous peritonitis in patients with liver cirrhosis. Zhonghua Gan Zang Bing Za Zhi. 2007;15:225.
6.
Yao W., Zhu Q., Yuan Y., Qiao M., Zhang Y., Zhai Z.Thymosin alpha 1 improves severe acute pancreatitis in rats via regulation of peripheral T cell number and cytokine serum level. J Gastroenterol Hepatol. 2007;22: 1866-1871.
7.
Rasi G., Silecchia G., Sinibaldi-Vallebona P., et al. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer. 1994;57:701-705.
